NanoLytx Overview
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
NanoLytx General Information
Description
Developer of a biological therapeutics system designed for the treatment of a neurological autoimmune condition. The company utilizes camelid-derived nanobody fusion proteins to neutralize a specific bacterial neurotoxin implicated in disease initiation, enabling the autoimmune therapeutics market to access a targeted, non-immunosuppressive approach that may reduce relapse rates, limit disease progression, and improve long-term outcomes through direct inhibition of the upstream pathological mechanism.
Contact Information
Website
www.nanolytx.comCorporate Office
- 500/504 East 63rd Street
- New York, NY
- United States
Corporate Office
- 500/504 East 63rd Street
- New York, NY
- United States
NanoLytx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 16-Aug-2026 | Completed | Out of Business | |||
| 1. Accelerator/Incubator | 01-Jan-2022 | Completed | Startup |
NanoLytx FAQs
-
Where is NanoLytx headquartered?
NanoLytx is headquartered in New York, NY.
-
What industry is NanoLytx in?
NanoLytx’s primary industry is Drug Discovery.
-
Is NanoLytx a private or public company?
NanoLytx is a Private company.
-
What is NanoLytx’s current revenue?
The current revenue for NanoLytx is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process